Full-time US Stock Trader | Focus on High-Potential Growth Stocks and Explosive Growth Opportunities | Capture 10x Stocks | Daily US Stock Insights and Real-Tim
On March 30, the S&P 500 index fell 7% year-to-date, marking one of its worst starts in history.
However, after experiencing the largest eight-week rally in history (a gain of 17%), the index is now up more than 10% year-to-date.
$MRK's novel lung cancer drug, sac-TMT—co-developed with China's Kelun-Biotech—delivered impressive results in Phase 3 clinical trials, reducing the risk of tumor progression by 65%; consequently, the company's stock price rose by nearly 3.5%.